Appili Therapeutics

115 articles about Appili Therapeutics

• 

  FDA Decisions: Novartis, Lilly Win Approvals in PNH, Blood Cancers

  12/7/2023

  With several key decisions still on the docket, December promises to be an exciting month for FDA watchers as 2023 comes to an end.

• Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024

  11/13/2023

  Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.

• Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy

  10/25/2023

  Appili Therapeutics Inc. today announced that the company secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (“USAFA”), who is working in partnership with the Defense Threat Reduction Agency (“DTRA”), the funding agency.

• Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update

  9/28/2023

  Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced the results from its annual meeting of shareholders.

• Appili Therapeutics Presents at the 10th International Tularemia Conference

  9/27/2023

  Appili Therapeutics Inc. today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023.

• 

  Appili Gets FDA Approval for Liquid, Oral Reformulation of Antibiotic Metronidazole

  9/26/2023

  The FDA on Monday approved the Canadian biopharma’s liquid antibiotic metronidazole, an alternative for patients who are unable to use pills or injections.

• Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension

  9/25/2023

  Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration ("FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).

• Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024

  8/11/2023

  Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.

• Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results

  6/23/2023

  Appili Therapeutics Inc. today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.

• Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole

  5/24/2023

  Appili Therapeutics Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled “ Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”.

• Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

  4/18/2023

  Appili Therapeutics Inc. today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on April 25 and 26, 2023.

• Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

  4/3/2023

  Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.

• Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

  2/14/2023

  Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.

• Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

  1/17/2023

  Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.

• Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

  1/13/2023

  Appili Therapeutics Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.

• Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

  11/14/2022

  Appili Therapeutics Inc. today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”) in partnership with the U.S. Air Force Academy (“USAFA”), will provide at least US$14 million in funding over two years to fund the development of ATI-1701.

• Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

  11/10/2022

  Appili Therapeutics Inc. today announced its financial and operational results for the second quarter of its fiscal year 2023, which ended on September 30, 2022.

• Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

  9/22/2022

  Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the results from its annual and special meeting of shareholders held earlier today.

• Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023

  8/12/2022

  Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of its fiscal year 2023, which ended on June 30, 2022.

• Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia

  8/2/2022

  Appili Therapeutics Inc. today announced that Armand Balboni, M.D, Ph.D, Chief Medical Officer of Appili, will participate at the seventh iteration of WorldLeish, from August 1 to 6 2022, and present an update on Appili program ATI-1801.